Valuation: Abivax

Market Cap 8.9B 10.38B 8.31B 7.63B 14.35B 992B 14.58B 98.11B 38.42B 498B 38.98B 38.13B 1,645B P/E 2026 *
-29.1x
P/E 2027 * -34.3x
Enterprise Value 7.8B 9.1B 7.29B 6.68B 12.57B 869B 12.78B 85.97B 33.66B 436B 34.15B 33.41B 1,442B EV / Sales 2026 *
104x
EV / Sales 2027 * 95.6x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 week-3.10%
Current month-2.82%
1 month-12.53%
3 months+0.39%
6 months-8.10%
Current year-14.20%
1 week 102.2
Extreme 102.2
106.2
1 month 102.2
Extreme 102.2
118.3
Current year 60.45
Extreme 60.45
139
1 year 60.3
Extreme 60.3
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.87
Extreme 3.87
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Fiscal year

Chief Executive Officer

17,728 0.0222%
7/11/26 Fiscal year

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.10%+75.08%+506.93% 10.38B
+0.83%+1.89%+1.99%+24.20% 50.5B
-0.62%+4.58%+487.47%+624.71% 46.01B
+2.09%+4.96%+20.59%+95.21% 42.85B
+3.85%+3.13%+29.60%+16.50% 41.03B
-0.72%-3.91%+17.87%+47.98% 32.02B
+3.04%+1.89%+31.62%+143.62% 16.98B
+4.33%+1.63% - - 17.05B
+1.84%+2.74%+4.65%+33.97% 14.3B
+3.87%+1.98%+82.99%+45.80% 13.84B
Average +1.87%+1.26%+83.54%+170.99% 28.5B
Weighted average by Cap. +1.58%+2.09%+103.50%+168.25%

Financials

2026 *2027 *
Net sales 74.92M 87.34M 69.96M 64.19M 121M 8.35B 123M 826M 323M 4.19B 328M 321M 13.84B 82.73M 96.45M 77.26M 70.88M 133M 9.22B 135M 912M 357M 4.62B 362M 354M 15.29B
Net income -265M -309M -248M -227M -427M -29.54B -434M -2.92B -1.14B -14.82B -1.16B -1.14B -48.99B -231M -269M -215M -198M -372M -25.71B -378M -2.54B -996M -12.89B -1.01B -988M -42.63B
Net Debt -1.1B -1.29B -1.03B -945M -1.78B -123B -1.81B -12.15B -4.76B -61.61B -4.83B -4.72B -204B -993M -1.16B -927M -850M -1.6B -111B -1.63B -10.94B -4.28B -55.47B -4.34B -4.25B -183B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-08-20 103.30 0.00% 15,405
26-08-19 €103.30 +0.39% 88,269
26-08-18 €102.90 -2.83% 61,836
26-08-17 €105.90 +3.12% 121,638
26-08-14 €102.70 -3.66% 102,656
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
103.30EUR
Average target price
138.97EUR
Spread / Average Target
+34.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock